Neutrophil-lymphocyte score: A novel prognostic scoring system that utilized the dynamic change of neutrophil, lymphocyte, and albumin and its comparison to other indices.

Authors

null

Songzhu Zhao

Center for Biostatistics, The Ohio State University, Columbus, OH

Songzhu Zhao , Mingjia Li , Daniel Spakowicz , Sandip H. Patel , Andrew Johns , Madison Grogan , Abdul Miah , Marium Husain , Kai He , Erin Marie Bertino , Peter G. Shields , Lai Wei , David Paul Carbone , Gregory Alan Otterson , Carolyn J Presley , Dwight Hall Owen

Organizations

Center for Biostatistics, The Ohio State University, Columbus, OH, The Ohio State University Wexner Medical Center, Division of Hospital Medicine, Columbus, OH, Division of Medical Oncology, Department of Internal Medicine & Department of Biomedical Informatics, Ohio State University, Columbus, OH, The Ohio State University Comprehensive Cancer Center, Department of Internal Medicine, Division of Medical Oncology, Columbus, OH, Dept. of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Ohio State University Wexner Medical Center, Columbus, OH, The Ohio State University Wexner Medical Center, Division of Medical Oncology, Columbus, OH, The Ohio State University Medical Center, Columbus, OH, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, The Ohio State University, Columbus, OH, Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH

Research Funding

Other
Research support provided by the REDCap project and The Ohio State University Center for Clinical and Translational Science grant support (National Center for Advancing Translational Sciences, Grant UL1TR002733). Dr. Owen is a Paul Calabresi Scholar suppo

Background: Indications for immune checkpoint inhibitor (ICI) in cancer care are expanding rapidly. There is increasing need for accurate decision tool to better guide treatment. We have constructed a new prognostic scoring system, neutrophil-lymphocyte score (NRS), based on the nonlinear dynamic change of neutrophil to lymphocyte ratio (NLR) in relation to survival over the first cycle of ICI treatment. We compared this novel system to existing indices such as NLR, lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR), Advanced Lung Cancer Inflammation Index (ALI), and Systemic Immune-inflammation Index (SII). Methods: This is a retrospective analysis of 837 patients at Ohio State University from 2011-18. Neutrophil (ANC), lymphocyte (ALC), platelet (plt), monocyte (AMC), albumin (alb), and body mass index (BMI) were collected at baseline. Repeat labs were collected at cycle 2. NLR = ANC/ALC, ALI = BMI x alb / NLR, LMR = ALC/AMC, SII = platelet x NLR, PLR = plt/ALC. NLR Ratio = baseline NLR / repeat NLR. Based on the association between NLR and the overall survival, we assigned 1 point (p) for baseline NLR < 0.7, 6p for 0.7 to < 2, 5p for 2 to < 3, 4 p for 3 to < 4, 3 for 4 to 5, 2p for 5 to < 9, and 1p for ≥9. We also assigned 1p for NLR ratio < 0.6, 2p for 0.6 to < 0.8, 3p for 0.8 to < 1.2, 5p for 1.25 to < 1.4, 3p for 1.4 to < 1.6, and 2p for ≥1.6. NLS = sum of these 2 scores . NLS_A = NLS*alb. Time-dependent receiver operator characteristic (ROC) curves with integrated time-dependent area under the curve (TD AUC) values were used to evaluate the predictive accuracy of each index for survival. Results: For baseline and repeat values, all indices were statistically significant (P < 0.001) in predicting survival. Baseline integrated TD AUC were: ALI 0.704, NLR 0.692, SII 0.663, LMR 0.645, and PLR 0.612. All of the repeat indices at cycle 2 had higher prognostic value than their baseline counterparts. Integrated TD AUC for indices at cycle 2 were: ALI 0.740 (with baseline BMI), NLR 0.729, SII 0.694, LMR 0.671, and PLR 0.652. NLS_A was a composite score based on the dynamic change of NLR from cycle 1 to 2 and the treatment alb with integrated TD-AUC at 0.754. Conclusions: Indices constructed from ANC, ALC, AMC, Plt, alb, and BMI can be obtained inexpensively and provide great prognostic value for pts on ICI. We have constructed a novel scoring system (NLS_A) and demonstrated its improvement over the current prognostic indices. Studies with a larger cohort are needed to further improve and validate this system.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3048)

DOI

10.1200/JCO.2020.38.15_suppl.3048

Abstract #

3048

Poster Bd #

112

Abstract Disclosures